Plasma-Derivative Allocation Control Director

The mandate

Markets reserve immunoglobulin, albumin and coagulation products independently even though they emerge from shared plasma pools, fractionation sequence and yield trade-offs. Collection litres are quoted as future cover before testing, pool release, process yield, presentation, national release and shelf life are known. Shortage escalations then compete at finished-product level after upstream choices are difficult to reverse. The defined problem is a portfolio allocation control joining yield-coupled supply to authorised patient demand, not plasma collection expansion or medical rationing.

The deliverable is a derivative allocation book containing plasma-pool and intermediate identity, expected and released yield, co-product coupling, presentation and market eligibility, expiry, patient-consequence demand classes, reservation confidence, substitution assumptions, shortage escalation and correction rules. Ten historic allocations and four live planning cycles form the casebook. Batch disposition, clinical guidance, price, reimbursement, collection network, production process and market contracting are excluded.

Four payment milestones mark distinct proof. The opening twelve working days reconcile pools, intermediates, products and ten disputed allocations. By day thirty-five, yield, eligibility and demand states must be usable by both plant and market owners. The middle half of the engagement carries two planning cycles and the release-delay scenario; the final month carries two further cycles before the accepted control book, trained-owner pack and 120-day implementation backlog are submitted.

Acceptance requires Supply, Manufacturing, Quality, Medical and country owners to reproduce how each pilot pool becomes eligible presentations and how each reservation consumes that constrained outcome. Four cycles must prevent double commitment, expose yield and release uncertainty, and show the patient consequence of co-product choices without asserting clinical priority. The president accepts when two teams reproduce allocations within tolerance and authorised functions confirm their release, medical and market boundaries.

The client will provide collection and pool records, testing, process plans, yield histories, intermediates, batch and release status, presentations, inventory, expiry, demand, reservations, shortages and market permissions. It will nominate plant, Quality, Medical and market owners and secure six reviews. Management retains production, batch release, medical policy, price, reimbursement, customer commitment and public-shortage communication authority.

Why this is external work

Collection teams see litres, plants see campaigns and markets see finished products, but portfolio scarcity is created at their intersections. In-house planning is also embedded in existing market commitments and cannot independently unwind them. A specialist fractionation operator can build comparable evidence without directing clinical use or selling collection capacity.

What you will own

• Reconcile plasma pools, intermediates, expected yield, released batches, presentations, market eligibility, expiry and reservations.
• Define supply confidence from collection through testing, pooling, fractionation, release, pack and national availability.
• Model co-product coupling so one allocation exposes its consequence for every related derivative and future campaign.
• Segment demand by authorised patient consequence, alternative availability, market status and credible consumption timing.
• Pilot four planning cycles and a release-delay scenario without converting supply rules into clinical rationing.
• Identify reservations that count untested litres, uncertain yield, unreleased batch or ineligible presentations as available.
• Deliver the accepted allocation book, case library, controlled model, owner training and funded 120-day backlog.

Candidate qualifications

• Designed global supply or allocation for plasma-derived therapies across collection, fractionation, release and market distribution.
• Has changed a finished-product commitment after plasma-pool yield or co-product consequence invalidated apparent cover.
• Understands testing, pooling, intermediate yield, presentation, release, expiry and national eligibility operationally.
• Can represent patient consequence without assuming clinician, Medical, Quality, price or public-allocation authority.
• Has reconciled plant, laboratory and market populations through shortage and materially uncertain yield cycles.
• Delivered portfolio controls that remained usable when pool release, process yield or country demand changed suddenly.

Non-negotiables

• Can complete six plant, laboratory, market or distributor reviews and four live cycles within four months.
• Will not sell plasma, collection services, fractionation capacity, market access, pricing or clinical advice.
• Accepts Manufacturing, Quality, Medical, country, customer and public-shortage authority boundaries.
• Brings direct fractionation portfolio knowledge; general pharmaceutical allocation experience alone is insufficient.

1. 49 words maximum. Describe a derivative allocation you changed after co-product yield exposed a hidden shortage.
2. 49 words maximum. How would you prevent untested plasma litres from becoming promised finished medicine?
3. 49 words maximum. Which presentation constraint can invalidate apparently adequate molecule-level inventory?